Truist lowered the firm’s price target on Disc Medicine (IRON) to $83 from $114 and keeps a Buy rating on the shares. The firm is updating its model to reflect the company’s Q4 results while noting that it now views clinical risk for bitopertin as elevated given the inherent variability of APOLLO Phase 3 trial primary endpoint, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine price target raised to $111 from $110 at Stifel
- Disc Medicine: Bitopertin’s De-Risked Path to Approval Supports Buy Rating
- Disc Medicine: Strong Cash Runway and Bitopertin Upside Support Buy Rating Despite Regulatory Setbacks
- Disc Medicine reports FY25 EPS ($6.01) vs ($3.96) last year
- Disc Medicine’s RALLY-IBD Trial Puts a Spotlight on Anemia Relief in IBD Patients